OSCR

Zinc oxide nanoparticles mitigate insulin resistance in a D-galactose-induced C57BL/6 mouse model.

A correction to this paper has been published: the notice, 42255446, from Europe PMC.

Overview

Authors: Kanagavalli Ramasubbu1, Devi Rajeswari V1
  1. Department of Biomedical Sciences, School of Biosciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India
Journal: Frontiers in endocrinology, volume 17, article 1819985
Dates: received 28 February 2026; accepted 27 April 2026; published online 12 May 2026
Type: Research article · Language: English
License: CC BY
Identifiers: DOI 10.3389/fendo.2026.1819985 · PMID 42255438 · PMCID PMC13237717 · OpenAlex W7160945350
Open access: gold, a free copy (OpenAlex)
Categories: mouse (organism), other condition (population), Alzheimer's / dementia (population), cellular / molecular (subfield)
Methods: Statistics
Keywords: amyloid-β deposition, insulin resistance, insulin signalling, neurodegeneration, ZnO nanoparticles
MeSH: Galactose*, Insulin Resistance*, Metal Nanoparticles*, Nanoparticles*, Zinc Oxide*, Amyloid beta-Peptides, Animals, Disease Models, Animal, Male, Mice, Mice, Inbred C57BL, Oxidative Stress, Phosphatidylinositol 3-Kinases, Signal Transduction (* major topic)
Topic: Antioxidants, Aging, Portulaca oleracea (Cellular and Molecular Neuroscience, Neuroscience), according to OpenAlex
Citations: not cited yet (Europe PMC); 90 references in the paper
Notices: A correction to this paper has been published (42255446, from Europe PMC)

Abstract

D-galactose promotes insulin resistance (IR) and neurodegeneration through hyperglycemia, advanced glycation end products (AGEs), oxidative stress, amyloid-β accumulation, and disruption of the insulin signalling pathway, leading to neuroinflammation and neuroapoptosis. The purpose of this study was to investigate the insulin signalling pathway and efficacy of ZnO nanoparticles (ZnO NPs) in alleviating brain IR and neurodegeneration via regulating IRS/PI3K/AGER/APP signalling. In this study, bioinformatic analysis of hub genes and PIP network revealed the interconnection between PI3K/Akt signalling pathway and neuroinflammation pathway leading to neurodegeneration. Further, in vivo analysis on 4-month-old C57BL/6 mice was randomised into control (NC), 50 mg/kg of D-galactose (DC), D-galactose + 450 μg/Kg of ZnO NPs (Z1), D-galactose + 650 μg/Kg of ZnO NPs (Z2), and D-galactose + 20 mg/kg of metformin (MF). Blood glucose, Amadori products, conjugated dienes, amyloid-β deposition, and gene and protein expression of the IRS/PI3K/AGER/APP signalling pathway were analysed. Our findings illustrated that ZnO NPs (Z1) alleviated hyperglycemia, cleared amyloid-β accumulation, maintained neural integrity, lessened fat deposition in the liver, and altered the expression of irs2, pi3k, ager, and app genes. Thus, ZnO NPs offer a therapeutic strategy for managing IR and neurodegeneration.

Reproduced under the paper's license (CC BY), from the paper cited above.

Code

The paper links to its data and to no code of its authors: see the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

Other data links

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

Reproduced under the paper's license (CC BY), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 28 September 2026: the first record

Recorded: type, language, journal, volume, pages, dates, 2 authors, 5 keywords, 14 MeSH terms, 90 references, 1 integrity notice.

Cite

This paper

Ramasubbu, K., & V, D. R. (2026). Zinc oxide nanoparticles mitigate insulin resistance in a D-galactose-induced C57BL/6 mouse model. Frontiers in endocrinology, 17, 1819985. https://doi.org/10.3389/fendo.2026.1819985

BibTeX

@article{ramasubbu2026zinc,
author = {Ramasubbu, Kanagavalli and V, Devi Rajeswari},
title = {{Zinc oxide nanoparticles mitigate insulin resistance in a D-galactose-induced C57BL/6 mouse model}},
journal = {Frontiers in endocrinology},
year = {2026},
month = may,
volume = {17},
pages = {1819985},
publisher = {Frontiers Media SA},
issn = {1664-2392},
doi = {10.3389/fendo.2026.1819985},
url = {https://doi.org/10.3389/fendo.2026.1819985},
pmid = {42255438},
pmcid = {PMC13237717}
}

RIS

TY - JOUR
AU - Ramasubbu, Kanagavalli
AU - V, Devi Rajeswari
TI - Zinc oxide nanoparticles mitigate insulin resistance in a D-galactose-induced C57BL/6 mouse model
T2 - Frontiers in endocrinology
J2 - Front Endocrinol (Lausanne)
PY - 2026
DA - 2026/05/12
VL - 17
SP - 1819985
SN - 1664-2392
PB - Frontiers Media SA
DO - 10.3389/fendo.2026.1819985
UR - https://doi.org/10.3389/fendo.2026.1819985
LA - en
ER -

CSL-JSON

{
"id": "10.3389/fendo.2026.1819985",
"type": "article-journal",
"title": "Zinc oxide nanoparticles mitigate insulin resistance in a D-galactose-induced C57BL/6 mouse model",
"container-title": "Frontiers in endocrinology",
"author": [
{
"family": "Ramasubbu",
"given": "Kanagavalli"
},
{
"family": "V",
"given": "Devi Rajeswari"
}
],
"container-title-short": "Front Endocrinol (Lausanne)",
"volume": "17",
"page": "1819985",
"DOI": "10.3389/fendo.2026.1819985",
"PMID": "42255438",
"PMCID": "PMC13237717",
"ISSN": "1664-2392",
"publisher": "Frontiers Media SA",
"URL": "https://doi.org/10.3389/fendo.2026.1819985",
"language": "en",
"issued": {
"date-parts": [
[
2026,
5,
12
]
]
}
}

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.3390/genes17020195
Region-Specific NRF2 Signaling in HIV-Associated Neurocognitive Disorders: A Transcriptomic and Computational Histology Study.
Journal: Genes
In common: Alzheimer's / dementia, other condition, cellular / molecular, 1 reference
[2] doi:10.3390/nu17243958
From Microbiota to Metabolomics: How <i>Corylus heterophylla</i> Fisch. Male Flower Extract Shields Mice from Cognitive Decline.
Journal: Nutrients
In common: Alzheimer's / dementia, mouse, cellular / molecular, 1 reference
[3] doi:10.1038/s42003-024-06242-1
Detecting the effect of genetic diversity on brain composition in an Alzheimer's disease mouse model.
Journal: Communications biology
In common: Alzheimer's / dementia, mouse, cellular / molecular, 1 reference
[4] doi:10.1002/alz.71471 [code]
How does type 2 diabetes modify the risk of Alzheimer's disease?
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
In common: Alzheimer's / dementia, other condition, cellular / molecular, 1 reference
[5] doi:10.1021/envhealth.4c00175
Disruption of Copper Redox Balance and Dysfunction under <i>In Vivo</i> and <i>In Vitro</i> Alzheimer's Disease Models.
Journal: Environment & health (Washington, D.C.)
In common: Alzheimer's / dementia, mouse, cellular / molecular, 1 reference
[6] doi:10.1016/j.ebiom.2025.105791
Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis.
Journal: EBioMedicine
In common: other condition, mouse, cellular / molecular, 1 reference
[7] doi:10.7717/peerj.15122
The modulatory effects of gut microbes and metabolites on blood-brain barrier integrity and brain function in sepsis-associated encephalopathy.
Journal: PeerJ
In common: other condition, mouse, cellular / molecular, 1 reference
[8] doi:10.34133/csbj.0085 [code]
A Systems-Level Transcriptomic Framework Identifies Shared Cellular Hubs in Osteoarthritis and Alzheimer's Disease.
Journal: Computational and structural biotechnology journal
In common: Alzheimer's / dementia, cellular / molecular, 1 reference
[9] doi:10.14336/ad.2023.0707 [code]
Alzheimer Disease Pathology and Neurodegeneration in Midlife Obesity: A Pilot Study.
Journal: Aging and disease
In common: Alzheimer's / dementia, other condition, 1 reference
[10] doi:10.1080/19336934.2025.2558387 [code]
VacQuant: a tool to quantify neurodegeneration and associated vacuolation in brain tissue.
Journal: Fly
In common: Alzheimer's / dementia, other condition, 1 reference

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.

Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.